Shares of Insulet Corporation surged 6.1% to $174.55 on July 6, as bargain hunters stepped in following months of punishing declines. The stock has cratered from a 52-week high of $354.88 to the mid-$140s, and investors are now weighing whether two device recalls and a securities fraud lawsuit have fully priced in the damage — or just the beginning of it.

Two Manufacturing Failures Wiped Out a Third of the Stock's Value

On March 12, Insulet disclosed a voluntary correction for specific lots of its wearable insulin pump pods after finding a manufacturing defect. Shares fell $16.23, or 6.9%, to $219.84.

Then on May 26, a second correction hit — this time spanning three product lines — due to a defect "that could result in insulin under-delivery." The stock fell another $7.79, or 5.1%, to $146.01.

The affected pods represented roughly 1.5% of annual production , but the repeat nature of the issue hammered investor confidence in Insulet's quality controls.

The Class Action Adds Legal Cost, Not Necessarily Existential Risk

The lawsuit, filed by Pomerantz LLP, alleges executives "failed to disclose that Insulet's manufacturing controls and procedures were defective" and that public statements were "materially false and misleading."

The class covers shareholders who bought between February 21, 2025 and May 26, 2026. Securities class actions in medtech often settle for a fraction of losses claimed, but legal fees and distraction can weigh on management through 2027.

The Business Itself Is Growing Fast — That's the Bull Case

In Q1 2026, Insulet beat estimates with adjusted earnings of $1.42 per share (vs. $1.22 consensus) on revenue of $761.7 million, up 33.9% year-over-year.

Management raised full-year constant-currency revenue guidance to 21%–23% growth and reiterated expectations for adjusted earnings-per-share growth above 25%.

The company also repurchased $300 million in stock, signaling internal confidence.

The Q2 Report on August 5 Is the Next Big Test

Insulet guided Q2 revenue to roughly $785 million at the midpoint — slightly below the $792 million analysts expected , leaving room for either a beat-driven rally or a disappointment that reignites the selloff. With the stock still more than 50% below its 52-week high, the August print will likely determine whether today's bounce is the start of a real recovery or a brief pause on the way down.